"Orna is developing a new treatment that uses circular RNA and specialized lipid particles to prompt a patient's own body to produce the cell therapies needed to fight disease. The technology has the potential to "unlock an entirely new class of genetic medicines and cell therapies for patients who today have limited or no treatment options," said Francisco Ramírez-Valle, senior vice president and head of Immunology Research and Early Clinical Development at Eli Lilly, in a statement."
""The world's most innovative biotech startups walk the line between science and science fiction, as they unravel the secrets of our genetic code, create miraculous cures for intractable diseases, design and power new foods for humanity, and invent new bioatlernatives to key materials and products," said Marco Ritcher, senior director of IP Analystics and Strategy for LexisNexis Intellectual Property Solutions."
Eli Lilly is acquiring Watertown-based Orna Therapeutics for $2.4 billion. Orna engineers immune cells inside the body using circular RNA and specialized lipid particles to prompt patients' bodies to produce needed cell therapies. Eli Lilly described the technology as having potential to unlock a new class of genetic medicines and cell therapies for patients with limited or no treatment options. LexisNexis named Orna the most innovative biotech startup globally. Eli Lilly is Indiana-based, the country's largest pharmaceutical company by market value, and has recently completed other multi-billion dollar biotech acquisitions.
Read at Boston.com
Unable to calculate read time
Collection
[
|
...
]